Dr. C. Michael Gibson, MS, MD, FACC | Harvard Medical School |
Dr. Gibson is an interventional cardiologist and chief of clinical research in the division of cardiology at Harvard’s Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. He received his masters and medical degree from the University of Chicago and was an intern, resident, and chief resident at the Brigham and Women’s Hospital, Harvard Medical School. He received his training as an interventional cardiologist and served as director of the Coronary Care Unit at Beth Israel Hospital, Harvard Medical School. In the past, Dr. Gibson served as Chief of Cardiology and Director of Interventional Cardiology at the West Roxbury Veterans Affairs Medical Center, Harvard Medical School. He also served as Vice Chairman of Medicine for clinical research and Director of Invasive Cardiology at Allegheny General Hospital. Finally, he served as Associate Chief of Cardiology, Chief of Interventional Cardiology, and Director of the Cardiac Catheterization Laboratory at University of California, San Francisco. Upon return to Boston he served for a period as Chief Academic Officer at Harvard Clinical Research Institute.
Dr. Gibson’s work has largely focused on the pathophysiology of acute coronary syndromes and the efficacy of pharmacologic and device-based therapies for coronary artery disease. He has directed the angiographic analysis of a wide variety of studies on acute coronary syndromes, imaging modality studies, percutaneous coronary intervention trials, peripheral interventional trials, angiogenesis trials, managed care analyses for HCFA, and atherosclerosis regression trials such as the NIH-sponsored Harvard Atherosclerosis Reversibility Project (HARP). Dr. Gibson is a principle investigator of multiple international acute coronary syndrome trials within the Thrombolysis in Myocardial Infarction (TIMI) Study Chairman’s Office. He is director of the TIMI Data Coordinating Center where he oversaw creation of the TIMI database that unifies data from over 15 years of TIMI studies in >75,000 patients at over 800 international centers. He invented the corrected TIMI frame count, an index of epicardial blood flow, and the TIMI myocardial perfusion grade, a measure of myocardial perfusion.
Dr. Gibson’s work has been presented in over 1000 manuscripts, review articles, abstracts, textbooks, trial summaries and textbook chapters. He is on the editorial board of Circulation. Dr. Gibson lectures internationally on the topics of acute MI, acute coronary syndromes, atherosclerosis, interventional cardiology and angiogenesis.